SEC Form 4 · accession 0001415889-15-002341
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank L Jaksch Jr.
Officer — CEO, PRESIDENT · Director
Period of report
Jul 6, 2015
Accepted (ET)
Jul 8, 2015 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy)F2,F1 | $1.22 | Jul 6, 2015 | A | 150,000 | A | Jul 6, 2016 | Jul 6, 2025 | Common Stock | 150,000 | 3,926,418 | D |
Explanation of responses
- F1Options vest 25% on July 6, 2016 with the remainder vesting 1/36th per month over three years thereafter.
- F2The total includes 3,776,418 options under different terms.